Compare Becton Dickinson and Co (BDX) vs Goldman Sachs Group Inc (GS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Goldman Sachs Group Inc — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Goldman Sachs Group Inc trades at $1,144 (market cap $336.31B). The key difference: Goldman Sachs Group Inc is far larger — about 8.1× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| BDX | GS | |
|---|---|---|
Market Cap | $41.51B | $336.31B |
Sector | Health | Financials |
52-Week High | $185.39 | $1.14K |
52-Week Low | $135.49 | $700.41 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | 1.58% |
Volume | — | 2,592,735 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Goldman Sachs (GS) trades at $1,140, up 8.04% in the past 24 hours, with a bullish technical outlook and strong earnings momentum after beating EPS estimates for three consecutive quarters. The stock shows robust fundamentals with a 29.89% net income margin and 15.69% ROE, supported by positive analyst sentiment and involvement in high-profile IPOs like Anthropic. Revenue growth accelerated to $58.28 billion in 2025, though cash flow trends remain volatile.
The outlook for GS is positive, driven by investment banking strength and AI-driven IPO opportunities, but risks include negative operating cash flows and elevated debt levels. Analysts maintain a consensus price target of $1,080, with 40% recommending Buy. Investors should weigh the company's profit growth against liquidity concerns and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →
